Background

This work evaluated the effects of proton pump inhibitors (PPIs) on cardiovascular events (CVEs) and inflammatory factors in patients with upper gastrointestinal bleeding (UGIB) undergoing dual antiplatelet therapy (DAPT) after percutaneous coronary intervention. Clinical data from these patients were analysis, intending to provide relevant theoretical evidence for clinical practice.

Materials and methods

Data of 166 patients who underwent percutaneous coronary intervention and developed UGIB while on DAPT at The First People’ Hospital of Linping District from April 2021 to April 2023 were retrospectively analyzed. The patients were rolled into two groups: those who received PPI treatment and those who did not, namely, PPI and non-PPI group, respectively. Furthermore, occurrence of CVEs and the levels of inflammatory factors of patients in all groups were statistically analyzed.

Results

In patients with UGIB, melena is a common presentation. The incidence of CVE in the PPI group showed no statistically significant difference compared to the control group, and there was no significant variance observed in the distribution of CVE incidence among different PPIs. However, levels of C-reactive protein (CRP) and tumor necrosis factor-alpha (TNF-α) were significantly lower in the PPI group compared to the non-PPI group (P < 0.05).

Conclusion

Melena was the most frequent clinical manifestation in UGIB patients. The use of PPIs did not increase the risk of CVEs, and different PPI drugs did not affect the occurrence of CVEs. Furthermore, PPIs lowered CRP and TNF-α levels in serum of these patients.

中文翻译：

---

质子泵抑制剂对接受双重抗血小板治疗的上消化道出血患者心血管事件和炎症因子的疗效和安全性

背景

这项工作评估了质子泵抑制剂（PPI）对经皮冠状动脉介入治疗后接受双重抗血小板治疗（DAPT）的上消化道出血（UGIB）患者心血管事件（CVE）和炎症因子的影响。对这些患者的临床资料进行分析，旨在为临床提供相关的理论依据。

材料和方法

回顾性分析2021年4月至2023年4月临平区第一人民医院接受经皮冠状动脉介入治疗并在DAPT期间发生UGIB的166例患者资料。将患者分为两组：接受 PPI 治疗的患者和未接受 PPI 治疗的患者，分别为 PPI 组和非 PPI 组。并对各组患者的CVE发生情况及炎症因子水平进行统计分析。

结果

在 UGIB 患者中，黑便是常见的表现。 PPI组CVE发生率与对照组相比无统计学显着性差异，且不同PPI间CVE发生率分布无显着差异。但 PPI 组 C 反应蛋白（CRP）和肿瘤坏死因子-α（TNF-α）水平显着低于非 PPI 组（P  < 0.05）。

结论

黑便是 UGIB 患者最常见的临床表现。使用PPI并不会增加CVE的风险，不同的PPI药物并不影响CVE的发生。此外，质子泵抑制剂还降低了这些患者血清中的 CRP 和 TNF-α 水平。